Answers are grounded in this paper and cite their sources.
Transjugular intrahepatic portosystemic stent-shunt (TIPS) was first reported in 1989 as a nonsurgical percutaneous method for treating patients suffering from severe end-stage portal hypertension symptoms with Child's stage C metabolic status at Freiburg University Hospital in Germany.1 Since then, TIPS has become a unique percutaneous technique for treating portal hypertension, and it has spread throughout the world. In the early 1990s, medical standards in China lagged far behind Western countries, and interventional radiology (IR) depended heavily on imported medical instruments. During that period, IR doctors and scientists who received training abroad came back to China and began to use stenting techniques at a time when imported stent products were extremely scarce. Dr. Ke Xu, who received IR training in Japan in the late 1980s, treated a male patient with cirrhosis combined with repeated hematemesis with TIPS in the First Hospital of China Medical University in June 1992, which was certified the first case of TIPS in China (Figure 1A). This was the first case in which a homemade “Z-type” stent was used for portosystemic shunt, and technical success was achieved after 12 h of effort (Figure 1B). After that, a series of TIPS cases were accomplished successfully at that hospital. Dr. Ke Xu and his team reported these cases at a China–Japan medical conference in 1992 and published the first paper on TIPS in China in the Chinese Journal of Radiology in 1993.2 TIPS training courses have been hosted by Dr. Ke Xu and his team every year thereafter. TIPS has become more common throughout China and was considered the most challenging IR procedure for quite a long time. Against the background of China's then lagging economy and technology, Chinese IR specialists actively followed the steps of the international IR community and independently manufactured stent products at a much lower price, leading to the rapid development of TIPS in China. After its initial bloom, TIPS experienced two decades of winter in China. In 1995, the number of TIPS-related Chinese publications had reached its first peak, indicating that TIPS had become widely recognized and applied. The prevalence of TIPS started to decrease after this peak in both the number of procedures performed and the number of papers published, mainly due to the high rate of shunt graft occlusion (Figure 1C) and shunt-related encephalopathy. It was reported that the occlusion rate of shunt graft after TIPS was 5%–64% within 1 year, 33%–70% within 2 years, and 60%–85% within 5 years; and the incidence of hepatic encephalopathy after TIPS was 30%, which was significantly higher than that after endoscopic sclerotherapy.3 People in the field of portal hypertension and TIPS all over the world started to study restenosis mechanisms and improve IR instruments. Among them, Dr. Gaojun Teng and his team from Zhongda Hospital of Southeast University found that the main mechanism of stent-graft occlusion was intrahepatic bile leakage inhibiting the endothelialization of scaffolds and promoting thrombosis within stent-grafts, rather than it being the proliferation of smooth muscle cells.4 A new modified stent graft called the VIATORR stent (Gore Corporation), which is partially covered by a tetrafluoroethylene membrane, became commercially available in the United States in 2004. With this novel stent graft, shunt restenosis decreased significantly, and TIPS entered another rapid phase of development. A few studies in this period showed that TIPS significantly decreased mortality in patients with cirrhosis and acute variceal bleeding. Some studies also showed that TIPS was more effective than endoscopic treatment in preventing and controlling gastrointestinal bleeding caused by portal hypertension without increasing the incidence of hepatic encephalopathy. However, VIATORR stents were not available in China until 2015, 10 years after their debut in Western countries. During this period, Chinese doctors created a new method by combining bare and covered stents (bare plus covered) to mimic the function of VIATORR stents. Given the import limitations in place at the time, this creation played an important role in TIPS in China during this window. Beginning in 2010, the number of TIPS procedures increased again, and more and more studies were being published in Chinese journals (Figure 1C). Since 2015, VIATORR stents have been widely used in clinical practice and research. The people cheered, “A second spring of TIPS comes in China.” In 2017, the Chinese TIPS Expert Consensus proposed that TIPS could be the preferred choice for the treatment of the rebleeding of esophagogastric varices after the failure of endoscopic hemostasis and medical treatment, especially for patients with poor liver function. Given the 30-year development of TIPS in China, it is not hard to see that IR techniques depended largely on the research and development capability of manufacturing enterprises. In recent years, with the rapid growth of the economy, the Chinese government has poured a large amount of resources into the research and development of IR products to improve China's state of dependence on imports and reduce the cost of medical care. China is home to half of the world's cases of hepatitis-related cirrhosis, and so has a huge market for TIPS products. Several Chinese enterprises have been producing homemade transjugular intrahepatic portosystemic puncture suits to replace the imported ones, which have dominated the market in this field for 30 years. The development of homemade, partially covered stents is also well underway. The Chinese government has also greatly accelerated the process for approving imported medical products. The second generation of VIATORR stent with variable dilation diameter was approved for clinical application in China in October 2021, just a few months after its approval in the US. Early application of novel imported IR products would undoubtedly accelerate its indigenization process in China. There is a profound need for high-quality clinical studies for clinical practice and guideline revision in China. According to data in the Web of Science, the number of relevant published papers in China ranks the third in the world, just behind the United States and Germany. However, most of these studies involve technique experience and single-center research, without high-level evidence. Therefore, these studies have limited value in clinical practice, and few of them have been cited in the most widely accepted international guidelines. Recently, doctors and researchers in China have come to pay more attention to the quality of clinical research. For example, Dr. Guohong Han from Xi'an carried out a randomized controlled trial (RCT) of TIPS with smaller-diameter stent grafts (8 mm), and the results indicate that the 8 mm stent could decrease the rate of postprocedure encephalopathy without increasing the rate of rebleeding.5 This study was subsequently cited in the European Association for the Study of the Liver's clinical practice guidelines for the management of patients with decompensated cirrhosis (2018). In 2016, Dr. Xiaolong Qi founded the Portal Hypertension Alliance in China (CHESS). CHESS has hosted a series of high-quality cohort and RCT studies, especially in the measurement of hepatic venous pressure gradients. The results of these studies have been published in high-impact journals, and are cited by the latest guidelines. With technical improvement, TIPS has come to play a more active role in the treatment of portal hypertension. Recent studies have indicated preemptive TIPS as the first-line treatment for improved outcomes in patients at high risk of variceal bleeding. Classification of TIPS moving from second-line to the first-line treatment has benefitted portal hypertension patients in selected populations, giving them a longer survival time than those with the regular first-line treatment of endoscopy plus medicine. At this point, it seems likely that more TIPS procedures will be performed in the future. Other than the technique itself and its efficacy, the quality of life of patients after TIPS has become a pronounced concern. A multidisciplinary team comprising gastroenterologists, gastrointestinal endoscopists, interventional radiologists, abdominal surgeons, and emergency intensive care unit staff is highly recommended before using TIPS. Under the joint efforts of the doctors, the scientists, the enterprises, and the governments in China, more novel homemade medical products, more precise treatments, and more intensive management could be developed and applied to portal hypertension patients. We in the field of cirrhosis and portal hypertension anticipate the third bloom of TIPS in China.
No takes yet. Share an insight, caveat, or question.
Shao et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: